Homologous Pfizer-BioNTech Booster Safe for Adolescents
Reactions to booster occur with similar frequency as after receipt of second vaccine dose, generally mild to moderate
White House Unveils New COVID-19 Response Strategy
Program to boost research into 'long COVID' has also been announced
ACP Issues Final Practice Points for Remdesivir Use in COVID-19
Consider treatment with remdesivir for five days for hospitalized COVID-19 patients who do not require invasive ventilation or ECMO
Risk for Progression to Severe COVID-19 Lower With Nirmatrelvir + Ritonavir
Treatment of symptomatic COVID-19 with nirmatrelvir plus ritonavir linked to 89 percent lower risk for progression versus placebo
Vaccination Ups Infection-Acquired Immunity Against SARS-CoV-2
Two doses of BNT162b2 vaccine linked to high short-term protection against infection, which wanes after six months
Nearly Half of 500 Million Free COVID-19 Tests Still Left
Americans have placed 68 million orders for four free rapid tests per family, but about 46 percent of the tests still available
Health Care Usage Down With DAA Therapy for Chronic Hep C
Rates of hospitalizations, liver-related ED visits lower for patients with sustained virological response to direct-acting antiviral therapy
Systemic Anticancer Treatment Not Tied to Higher COVID-19 Mortality
Receipt of immunotherapy compared with no cancer treatment in the four weeks preceding COVID-19 diagnosis associated with lower mortality
Asymptomatic SARS-CoV-2 Infection Seems to Be Less Common
Study showed 12 of 12 health care workers diagnosed with SARS-CoV-2 infection had at least mild symptoms
Children, Adults Can Transmit SARS-CoV-2 to Household Contacts
Secondary infection risks were lower for primary cases aged 12 to 17 years compared with those aged 18 to 49 years
